- Home
- CYH vs AQST Comparison
CYH vs AQST Comparison
Compare CYH & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYH
- AQST
- Stock Information
- Founded
- CYH 1985
- AQST 2004
- Country
- CYH United States
- AQST United States
- Employees
- CYH N/A
- AQST N/A
- Industry
- CYH Hospital/Nursing Management
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- CYH Health Care
- AQST Health Care
- Exchange
- CYH Nasdaq
- AQST Nasdaq
- Market Cap
- CYH 410.5M
- AQST 390.4M
- IPO Year
- CYH 1991
- AQST 2018
- Fundamental
- Price
- CYH $3.08
- AQST $4.94
- Analyst Decision
- CYH Hold
- AQST Strong Buy
- Analyst Count
- CYH 8
- AQST 7
- Target Price
- CYH $3.57
- AQST $10.29
- AVG Volume (30 Days)
- CYH 1.5M
- AQST 2.3M
- Earning Date
- CYH 10-22-2025
- AQST 11-03-2025
- Dividend Yield
- CYH N/A
- AQST N/A
- EPS Growth
- CYH N/A
- AQST N/A
- EPS
- CYH N/A
- AQST N/A
- Revenue
- CYH $12,647,000,000.00
- AQST $44,132,000.00
- Revenue This Year
- CYH N/A
- AQST N/A
- Revenue Next Year
- CYH $2.46
- AQST $51.50
- P/E Ratio
- CYH N/A
- AQST N/A
- Revenue Growth
- CYH 0.81
- AQST N/A
- 52 Week Low
- CYH $2.24
- AQST $2.12
- 52 Week High
- CYH $6.29
- AQST $5.80
- Technical
- Relative Strength Index (RSI)
- CYH 62.03
- AQST 61.01
- Support Level
- CYH $2.87
- AQST $4.78
- Resistance Level
- CYH $3.13
- AQST $5.27
- Average True Range (ATR)
- CYH 0.13
- AQST 0.30
- MACD
- CYH 0.03
- AQST 0.02
- Stochastic Oscillator
- CYH 88.64
- AQST 64.71
About CYH Community Health Systems Inc.
Community Health Systems Inc is a publicly owned hospital operator in the United States. The company also owns four home health agencies and provides management and consulting services to independent hospitals. The firm derives revenue through a broad range of general and specialized hospital healthcare services and outpatient services.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.